1. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates Publication: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2017 Subject(s): Drug CostsDrug Industry -- economicsMedicaid -- economicsPharmaceutical Preparations -- classificationPharmaceutical Preparations -- economicsInsurance, Health, ReimbursementInsurance, Pharmaceutical ServicesHumansUnited StatesUnited States. Department of Health and Human Services.Centers for Medicare & Medicaid Services (U.S.)
2. Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters Publication: Washington, DC : United States Government Accountability Office, November 2017 Subject(s): Drug CostsDrug Industry -- economicsEconomics, Pharmaceutical -- trendsPharmaceutical Research -- economicsPharmaceutical Research -- trendsAntitrust LawsBiological Products -- economicsDrug Approval -- economicsDrug Development -- economicsDrug Development -- trendsEconomic CompetitionForecastingOrphan Drug Production -- economicsTaxesHumansUnited StatesNational Institutes of Health (U.S.)